Oman Diabetes Care Drugs And Devices Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

The market comprises insulin therapies, oral antidiabetic drugs, blood glucose monitoring systems, insulin delivery devices, and continuous glucose monitoring equipment distributed through hospitals, clinics, pharmacies, and home care channels. Oman maintains one of the Middle East's highest diabetes prevalence rates, affecting roughly one in five adults, which sustains robust and continuous demand for diabetes management solutions. Public healthcare initiatives, health insurance expansions, and private sector investment collectively support market accessibility and growth across urban and rural regions.

• •Diabetes prevalence in Oman ranges between 15-20% of the adult population, significantly above global averages
• •The Ministry of Health operates a comprehensive network of primary healthcare centers providing diabetes screening and treatment nationwide
• •Both public hospitals and private clinics contribute to market demand, with insurance coverage improving patient access to medications and devices

Increasing prevalence of lifestyle-related conditions including obesity, physical inactivity, and poor dietary patterns has accelerated diabetes incidence across all demographic segments in Oman. An aging population requiring ongoing chronic disease management expands the base of patients requiring continuous medication, monitoring, and medical intervention. Oman Vision 2040 healthcare modernization initiatives, increased health spending, and expanded insurance coverage collectively drive market growth through infrastructure development and technology adoption.

• •Rising obesity rates and sedentary lifestyles contribute to growing type 2 diabetes burden across younger age groups
• •Government health policy priorities under Oman Vision 2040 emphasize non-communicable disease prevention and management
• •Expanding health insurance coverage and government procurement programs improve patient access to diabetes treatments

The market divides into pharmaceutical drugs including insulins, GLP-1 receptor agonists, SGLT2 inhibitors, and oral antidiabetic agents, alongside devices such as blood glucose meters, test strips, insulin pumps, continuous glucose monitors, and smart insulin pens. Muscat Governorate represents the largest regional market due to concentrated healthcare facilities, higher population density, and greater economic resources. Other governorates including Dhofar, Al Batinah North, Al Batinah South, and Al Dakhiliyah demonstrate growing demand as healthcare infrastructure expands beyond the capital region.

• •Insulin products constitute the dominant drug segment, with basal and rapid-acting formulations commanding the largest share
• •Blood glucose monitoring devices and test strips represent the primary devices category by revenue
• •Urban centers generate the majority of current market value while regional and rural healthcare expansion creates new growth opportunities

What are the recent trends and outlook?

Digital health adoption, connected diabetes management devices, and telemedicine platforms are gaining traction as patients and providers seek remote monitoring and personalized care solutions. The pipeline of advanced therapeutics including next-generation insulin analogs, GLP-1 dual agonists, and non-invasive glucose monitoring technologies presents significant future growth potential. Government localization initiatives, pharmaceutical manufacturing incentives, and evolving procurement policies may increasingly influence competitive positioning and market accessibility over the forecast horizon.

• •Integration of digital health platforms and smartphone-connected devices for real-time diabetes management is accelerating
• •Government economic diversification policies may promote local pharmaceutical manufacturing and reduce import dependency
• •Growing patient education initiatives and screening programs are expected to increase early diagnosis rates and treatment initiation